Incidence, Treatment, and Survival Patterns for Sacral Chordoma in the United States, 1974-2011

被引:34
作者
Yu, Esther [1 ]
Koffer, Paul P. [1 ]
DiPetrillo, Thomas A. [1 ,2 ]
Kinsella, Timothy J. [2 ]
机构
[1] Tufts Med Ctr, Radiat Oncol, Boston, MA 02111 USA
[2] Brown Univ, Warren Alpert Med Sch, Radiat Oncol, Providence, RI 02912 USA
来源
FRONTIERS IN ONCOLOGY | 2016年 / 6卷
关键词
chordoma; IMRT; protons; SBRT; heavy ion; CARBON ION RADIOTHERAPY; RADIATION-THERAPY; PHASE-II; CHONDROSARCOMAS; MANAGEMENT; SPINE; EXPERIENCE;
D O I
10.3389/fonc.2016.00203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Sacral chordomas represent one half of all chordomas, a rare neoplasm of notochordal remnants. Current NCCN guidelines recommend surgical resection with or without adjuvant radiotherapy or definitive radiation for unresectable cases. Recent advances in radiation for chordomas include conformal photon and proton beam radiation. We investigated incidence, treatment, and survival outcomes to observe any trends in response to improvements in surgical and radiation techniques over a near 40-year time period. Materials and methods: Three hundred forty-five microscopically confirmed cases of sacral chordoma were identified between 1974 and 2011 from the surveillance, epidemiology, and end results program of the National Cancer Institute. Cases were divided into three cohorts by calendar year, 1974-1989, 1990-1999, and 2000-2011, as well as into two groups by age <= 65 versus > 65 to investigate trends over time and age via Chi-square analysis. Kaplan-Meier analyses were performed to determine effects of treatment on survival. Multivariate Cox regression analysis was performed to determine predictors of overall survival (OS). Results: Five-year OS for the entire cohort was 60.0%. OS correlated significantly with treatment modality, with 44% surviving at 5 years with no treatment, 52% with radiation alone, 82% surgery alone, and 78% surgery and radiation (p < 0.001). Age >65 was significantly associated with non-surgical management with radiation alone or no treatment (p < 0.001). Relatively, fewer patients received radiation between 2000 and 2011 compared to prior time periods (p = 0.03) versus surgery, for which rates which did not vary significantly over time (p = 0.55). However, 5-year OS was not significantly different by time period. Age group and treatment modality were predictive for OS on multivariate analysis (p < 0.001). Conclusion: Surgery remains an important component in the treatment of sacral chordomas in current practice. Fewer patients were treated with radiation more recently despite advances in photon and proton beam radiation. OS remains unchanged. Additional analyses of margin status, radiation modality, and local control in current practice are warranted.
引用
收藏
页数:5
相关论文
共 23 条
  • [1] Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO
  • [2] 2-1
  • [3] Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
  • [4] Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base
    Debus, J
    Schulz-Ertner, D
    Schad, L
    Essig, M
    Rhein, B
    Thillmann, CO
    Wannenmacher, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 591 - 596
  • [5] Long-Term Results of Phase II Study of High Dose Photon/Proton Radiotherapy in the Management of Spine Chordomas, Chondrosarcomas, and Other Sarcomas
    Delaney, Thomas F.
    Liebsch, Norbert J.
    Pedlow, Frank X.
    Adams, Judith
    Weyman, Elizabeth A.
    Yeap, Beow Y.
    Depauw, Nicolas
    Nielsen, G. Petur
    Harmon, David C.
    Yoon, Sam S.
    Chen, Yen-Lin
    Schwab, Joseph H.
    Hornicek, Francis J.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (02) : 115 - 122
  • [6] Operative management of sacral chordoma
    Fuchs, B
    Dickey, ID
    Yaszemski, MJ
    Inwards, CY
    Sim, FH
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2005, 87A (10) : 2211 - 2216
  • [7] Sacral chordoma: Can local recurrence after sacrectomy be predicted?
    Hanna, S. A.
    Aston, W. J. S.
    Briggs, T. W. R.
    Cannon, S. R.
    Saifuddin, A.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2008, 466 (09) : 2217 - 2223
  • [8] Challenges in Linear Accelerator Radiotherapy for Chordomas and Chondrosarcomas of the Skull Base: Focus on Complications
    Hauptman, Jason S.
    Barkhoudarian, Garni
    Safaee, Michael
    Gorgulho, Alessandra
    Tenn, Steven
    Agazaryan, Nzhde
    Selch, Michael
    De Salles, Antonio A. F.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (02): : 542 - 551
  • [9] TREATMENT OF CHORDOMAS WITH CYBERKNIFE: GEORGETOWN UNIVERSITY EXPERIENCE AND TREATMENT RECOMMENDATIONS
    Henderson, Fraser C.
    McCool, Kyle
    Seigle, Juliet
    Jean, Walter
    Harter, William
    Gagnon, Gregory J.
    [J]. NEUROSURGERY, 2009, 64 (02) : A44 - A53
  • [10] Postoperative Proton Therapy for Chordomas and Chondrosarcomas of the Spine Adjuvant Versus Salvage Radiation Therapy
    Holliday, Emma B.
    Mitra, Hari S.
    Somerson, Jeremy S.
    Rhines, Laurence D.
    Mahajan, Anita
    Brown, Paul D.
    Grosshans, David R.
    [J]. SPINE, 2015, 40 (08) : 544 - 549